Cancer is a terrible disease and many of its treatments are harsh, sometimes causing more damage than the disease. While many companies are working on dramatic new treatments, there are opportunities to make significant improvement to the present ones. This is NanoTherapies’s present objective. Achieving it creates a very sizable business opportunity while improving patient care.

NanoTherapies plans to capitalize on this opportunity by employing an efficient strategy for commercialization, NDAs under 505(b) (2), and using external resources with the requisite skills and expertise, coordinated outsourcing. Used together these will minimize capital requirements and shorten the time to revenue and earnings thus crating significant value for investors.  The Company’s lead product is a NanoJacketed Version of an existing and approved medication. The company intends to create a patent protected version of this medication that achieves sales of greater than $500 million a year.